Abstract | OBJECTIVE: METHODS: RESULTS:
Avastin exhibited cell inhibited rate of 24.21%, 26.26% and 34.58% at 50, 100 and 200 mg/L, respectively. When experiment was terminated, the tumor volume in the PBS-treated mice was (1 860.10+/-146.96) mm3, being significantly larger than that in the mice that were treated by Avastin [(681.45+/-63.01) mm3, P<0.01]. Avastin-treated tumors showed decreased tumor cell proliferation and increased cell apoptosis. The VEGF level in mice treated with Avastin [(594.65+/-118.79) ng/L] was significantly lower than that in PBS-treated mice [(802.24+/-238.41) ng/L, P<0.05]. CONCLUSION: The results suggest that topically applied Avastin provides an effective and safe approach to treat hemangioendotheliomas and might be used as a novel treatment of angiomatous diseases in the future.
|
Authors | Zhen-qi Xu, Yu Liu, Yi-xiang Wang, Wei Zhang, Fu-yun Zhao |
Journal | Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
(Beijing Da Xue Xue Bao Yi Xue Ban)
Vol. 41
Issue 1
Pg. 105-8
(Feb 18 2009)
ISSN: 1671-167X [Print] China |
PMID | 19221576
(Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- vascular endothelial growth factor A, mouse
- Bevacizumab
|
Topics |
- Angiogenesis Inhibitors
(pharmacology, therapeutic use)
- Animals
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Female
- Hemangioendothelioma
(drug therapy, pathology)
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Neoplasm Transplantation
- Skin Neoplasms
(drug therapy, metabolism)
- Vascular Endothelial Growth Factor A
(metabolism)
|